

Introduction

“The most effective strategy against antimicrobial resistance is to get the job done right the first time...thereby defeating resistance before it starts.”
— World Health Organization, 2000

Fluoroquinolones play an essential role in treating respiratory, genitourinary, and skin infections. High-dose, short-course fluoroquinolone therapy represents a scientifically sound approach to leveraging the concentration-dependent bacterial killing activity and rates of the fluoroquinolones. This pharmacologic approach may prove to be clinically invaluable with decreased emergence of bacterial mutation and resistance, lower total drug exposure

to the patient and environment, and increased patient compliance. However, fluoroquinolones differ in their safety profiles, and so it may not be possible to increase the dose for all fluoroquinolones.

This **Clinical Cornerstone**[®] supplement focuses on the scientific and clinical rationale behind higher fluoroquinolone dosing with an emphasis on the potential benefits as well as safety considerations behind high-dose, short-course therapy for community-acquired pneumonia.

John G. Bartlett, MD
Guest Editor